- Trial phase
- Approved / marketed (legacy product)
- Time to market
- Already on the market, a long-approved, marketed chemotherapy (US sales began in the mid-2000s); no further approval needed.
- Why 2/10
- No hard, dated catalyst exists for Abraxane in the next ~12 months, it is already approved and marketed, with zero FDA actions, catalysts, or readouts tied to it in the local data, and it is a minor legacy product inside a ~$129B diversified pharma, so even a favorable development would barely move BMY.
Do not trade BMY on Abraxane, it is a declining, generics-exposed legacy chemotherapy with no scheduled catalyst and immaterial weight in a ~$129B company. If you hold BMY, the stock thesis is driven by the Growth Portfolio (Opdivo, Eliquis, Breyanzi) and pipeline PDUFAs, not this drug; track Abraxane only as a line item within Legacy Portfolio erosion at quarterly earnings.
Price Chart
Executive Summary
Abraxane (nab-paclitaxel, development code ABI-007) is a long-approved, mature chemotherapy that came to Bristol Myers Squibb through its 2019 acquisition of Celgene (which had bought Abraxis BioScience). Internal SecBot data confirms BMY (NYSE) is the current owner, Abraxane appears in BMY's Q2 2026 earnings-filing drug list, and that the drug is still widely used as a chemotherapy backbone, especially the gemcitabine/Abraxane (GnP) regimen in pancreatic cancer. It sits in BMY's "Legacy Portfolio," which fell 4% year-over-year in Q2 2026 amid generic erosion, and there are no regulatory catalysts scheduled for it.
How It Works
Abraxane is paclitaxel, a classic chemotherapy that stops cancer cells from dividing, wrapped in tiny nanoparticles of human albumin protein. This "protein-bound" packaging lets it be infused without the harsh solvent used in older Taxol, which historically reduced infusion-allergic reactions and allowed different dosing.
Trial Status
No BMS-sponsored registrational trials for Abraxane appear in the ingested pipeline; it is used as an established chemotherapy backbone in outside Phase 2/3 studies (pancreatic cancer gemcitabine/Abraxane combos, triple-negative breast cancer, NSCLC, biliary tract). Local trial/event records show completed and ongoing academic and industry studies combining nab-paclitaxel with newer agents.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Abraxane itself (no PDUFA, pivotal readout, or label decision in the next ~12 months).
- Company-level, not drug-level: BMY quarterly earnings will keep reporting Legacy Portfolio erosion including Abraxane; BMY's own pipeline PDUFAs (e.g., iberdomide Aug 17, 2026) are the real stock drivers.
- Watch whether any partner trial using gemcitabine/Abraxane (e.g., Alpha Tau's pancreatic-cancer IMPACT expansion, per local event records) produces data that could modestly influence Abraxane utilization.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report